Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefotaxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.68 |
| ▸ | PPARG | P37231 | 3/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 3/20 | 0.68 |
| ▸ | SLC22A11 | Q9NSA0 | 3/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | APEX1 | P27695 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefoxitin SCHEMBL9450006 | 0.88 | NR1I2 (0.81) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Ceftazidime SCHEMBL6698665 | 0.86 | NR1I2 (0.66) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefoxitin SCHEMBL11165402 | 0.83 | NR1I2 (0.73) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL10337429 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL1583477 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL16072837 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL5441797 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| SCHEMBL9660046 | 0.83 | NR1I2 (0.88) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL17422140 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL3731937 | 0.83 | NR1I2 (1.00) | MAPTNR1I2PPARGSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | MAPT 3729/4885NR1I2 107/4885PPARG 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.